Isotechnika Inc.

Isotechnika Initiates Canadian Phase III Psoriasis Trial

    Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that a Canadian Phase III trial for its lead immunosuppressive drug candidate, ISA247 for the treatment of moderate to severe psoriasis has commenced. As of today, a total of 21 patients have been enrolled and dosing has begun.

    The Phase III trial will be performed over a twenty-four week period at thirty-three centers across Canada involving a total of 400 patients with severe psoriasis. It will be conducted as a randomised, double-blind study with 100 patients receiving the high dose (0.4 mg/kg twice daily), 100 patients receiving the anticipated therapeutic dose (0.3 mg/kg twice daily), 100 patients receiving the low dose (0.2 mg/kg twice daily) and 100 patients receiving placebo. Subsequent to the first 12 weeks, those receiving placebo will move into the mid dose range dose of 0.3 mg/kg twice daily for the remaining 12 weeks of the study. All doses of drug will be administered as soft gelatine capsules administered orally.

    The primary and secondary endpoints of the trial include a 75% reduction in the psoriasis area and severity index (PASI), maintenance of stable kidney function, and assessment of quality of life. Periodic blood specimens will be collected throughout the study to provide additional pharmacokinetic and pharmacodynamic data on ISA247.

    "The commencement of this trial is a very significant milestone for Isotechnika," stated Dr. Randall Yatscoff, Isotechnika's President and Chief Operating Officer. "The Company's drug development programme continues to  move forward and meet the timelines outlined for ISA247. We remain focused on  our ultimate goal of improving the quality of life of patients suffering from such a debilitating disease."

    The management team will provide an overview of the Phase III trial to the investment community this morning commencing at 9:15 a.m. EST/ 7:15 a.m. MST. All Interested parties can access the live web cast (listen only mode) by entering http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID(equal sign)975480 in their web browser. Alternatively, you may access the web cast through our corporate Web site at www.isotechnika.com. The web cast will be archived for a 90 day period through the web cast archives at www.newswire.ca.

      About Isotechnika Inc.
      ----------------------

    Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in  medicinal chemistry and immunology, the Company is focused on the discovery  and development of novel immunosuppressive therapeutics that are safer than  currently available treatments. Its entrepreneurial management and  world-class team of scientists are building a pipeline of immunosuppressive  drug candidates for use in the prevention of organ rejection in  transplantation and in the treatment of autoimmune diseases. Isotechnika  looks to become the leader in development of immunosuppressant therapies.

    Isotechnika's lead drug, ISA247, presently referred to as trans-ISA247, is an immunosuppressant that has successfully completed a Phase II trial for psoriasis and Phase IIa trial for kidney transplantation. Isotechnika recently expanded its product pipeline by developing two additional novel immunosuppressive compounds, TAFA93 and TKB662. TAFA93 is a novel small molecule mTOR inhibitor, a class of drugs currently used in the prevention of organ rejection in transplantation and as a coated stent therapy in the treatment of coronary artery disease. Pre-clinical studies of TKB662 have demonstrated inhibition of T cell and B cell activation and proliferation through multiple mechanisms of action including the inhibition of lymphocyte phosphorylation activity. As both TAFA93 and TKB662 have distinct mechanisms of action from calcineurin inhibitors such as ISA247 they have the potential to be administered as complementary therapies in both prevention of organ rejection and treatment of autoimmune diseases.

    In addition to the Company's drug pipeline, Isotechnika also has a diagnostic division, which includes the Helikit(TM) and Diatest(TM) breath kits. The Helikit(TM), a 13C breath test is used for the detection of H.pylori, a bacterium that infects a large portion of the population. The Helikit(TM) is currently sold internationally. The Diatest(TM), a 13C glucose breath test is used for the detection of insulin resistance.

    Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol ISA. More information on Isotechnika can be found at www.isotechnika.com.

      Forward-Looking Statements
      --------------------------

    This press release may contain forward-looking statements. Forward-  looking statements, including the Company's belief as to the potential of its  products, the Company's expectations regarding the issuance of additional  patents and the Company's ability to protect its intellectual property,  involve known and unknown risks and uncertainties, which could cause the  Company's actual results to differ materially from those in the forward-  looking statements. Such risks and uncertainties include, among others, the  availability of funds and resources to pursue research and development  projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and  trials, the Company's ability to successfully commercialize its products, the  ability of the Company to defend its patents from infringement by third  parties, and the risk that the Company's patents may be subsequently shown to  be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for  additional information on risks and uncertainties relating to the forward-  looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.newsaktuell.ch

Contact:
For further information: Dr. Randall Yatscoff, President & COO,
Isotechnika Inc., Phone: +1-780-487-1600 Ext.246, Fax:
+1-780-484-4105, Email: ryatscoff@isotechnika.com; Stephanie
Gillis-Paulgaard, Manager, Corporate Communications, Isotechnika
Inc., Phone: +1-780-487-1600 Ext. 243, Fax: +1-780-484-4105,
E-mail:sgillis-paulgaard@isotechnika.com; Archived images on this
organization are available through CNW E-Pix at
http://www.newswire.ca. Images are free to members of The Canadian
Press. To request a free copy of this organization's annual report,
please go to http://www.newswire.ca and click on reports@cnw.



Weitere Meldungen: Isotechnika Inc.

Das könnte Sie auch interessieren: